Recent Articles

Found 40 Results
Page 1 of 4

Immuneering Appoints Michael Bookman as General Counsel and Secretary

Executive with Extensive Legal Expertise in Life Sciences Strengthens Leadership Team CAMBRIDGE, Mass., July 20, 2021— Immuneering Corporation (“Immuneering”), a private biopharmaceutical company advancing a robust pipeline of oncology and…


Immuneering Expands Board of Directors with Appointment of Ann E. Berman

Former Chief Financial Officer of Harvard University Strengthens Board with Financial Expertise and Considerable Board Experience   CAMBRIDGE, Mass., July 14, 2021 (GLOBE NEWSWIRE) — Immuneering Corporation (“Immuneering”), a private…


Immuneering Expands Board of Directors with Addition of Senior Biotechnology Executive Laurie Keating

CAMBRIDGE, Mass., April 27, 2021 (GLOBE NEWSWIRE) — Immuneering Corporation (“Immuneering”) today announced the addition of Laurie Keating to its board of directors. Ms. Keating brings more than 25 years…


Immuneering Appoints Biren Amin, M.B.A., as Chief Financial Officer

CAMBRIDGE, Mass., April 06, 2021 (GLOBE NEWSWIRE) — Immuneering Corporation today announced the appointment of Biren Amin, M.B.A., as Chief Financial Officer. Mr. Amin comes to Immuneering from Jefferies Financial…


Disease Cancelling Technology Emulates Sound Cancelling Technology to Mute Cancer

In this article by Gail Dutton, our co-founder and CEO Ben Zeskind discusses Immuneering’s proprietary Disease Cancelling Technology platform, and our growing pipeline of medicines targeting signaling pathways that are…


Disease-cancelling drugs: Immuneering raises $62m in Series B round

In this article by Allie Nawrat, our co-founder and CEO Ben Zeskind discusses Immuneering’s recent financing of $62m, in an oversubscribed Series B round led by high-profile life science investors….


Immuneering secures $62M series B to advance tech-driven pipeline

In this article by Michael Fitzhugh, Immuneering co-founder and CEO Ben Zeskind discusses the company’s recent oversubscribed Series B financing, which raised a total of $62M to advance its Disease…


Immuneering Completes Oversubscribed $62 Million Series B Financing

Financing to support advancement of Immuneering’s lead drug programs targeting cancers driven by alterations in the RAS/MAPK pathway and pipeline development of earlier programs in neuroscience and immuno-oncology.


Biomarkers Show the Power of Contexualization

In this Genetic Engineering & Biotechnology News article by Richard A. Stein, Immuneering’s Head of Neuroscience J.L. Ross, Ph.D. discusses the company’s integration of biomarkers with bioinformatic, proteomic, and gene signature information…


Silencing gene expression to cure complex diseases

In this article by Zach Winn, Immuneering co-founder and CEO Ben Zeskind discusses his journey from MIT undergraduate to biotech entrepreneur. He speaks to the company’s decade-plus of experience helping…


Page 1 of 4